BBK Worldwide, a patient recruitment company, has launched Study eBinder 3.0, the latest generation of its novel clinical trial management tool. The release of this product builds upon earlier models by offering a more customized and tailored tablet experience for on-the-go study teams. Utilizing BBK’s patented TrialCentralNet (TCN) patient recruitment portal, Study eBinder 3.0 provides more than 300 real-time reports and a protected instant messaging system for sponsors to connect directly with physician investigators and site staff.
“The conversation is no longer about tech adoption as today’s tablet culture continues to widen,” said Matt Kibby, principal, technology and innovation, BBK Worldwide. “Thirty-five percent of Americans own tablets, and that number is growing.” BBK’s Study eBinder 3.0 is fully customizable for both the sponsor’s brand and content.
“Sites are quick to adopt this new technology,” said Lucas Garmon, media strategist, BBK Worldwide. “Universal implementation of online resources across devices guarantees individuals have the most critical information at all times. From coordinating study appointments to reviewing the informed consent with patients, we have seen sites begin to rely on their ability to manage studies remotely.”
Study eBinder 3.0 is also available in a restricted sponsor view, as well as a patient view, which includes condition-specific information, tips for study participation and customized retention tools.